GUERBET : 1st quarter 2017 revenue
April 27 2017 - 11:47AM
€197.3 million at constant exchange
rates, up 7.4%
Confirmation of
the trend that started in the fourth quarter of 2016
Villepinte, April
27, 2017 - Guerbet (FR0000032526 GBT), a
global specialist in contrast agents and solutions for medical
imaging, is publishing revenue of €203.1 million for the 1st
quarter of 2017, up by 10.5% at current exchange rates (7.4% at
constant exchange rates) compared with the same period last
year.
Consolidated
Group revenue (IFRS)
In
millions of euros
at March 31, 2017 |
Change (%) |
2017
at current exchange rates
|
Change (%) |
2017
at constant exchange rates
|
2016
|
Sales in
Europe |
+1.1% |
94.3 |
+2.2% |
95.3 |
93.2 |
Sales in
Other Markets |
+20.3% |
108.8 |
+12.7% |
102.0 |
90.5 |
Total 1st quarter revenue |
+10.5% |
203.1 |
+7.4% |
197.3 |
183.7 |
Activity is growing in Europe and
in the Other Markets. The 1st quarter 2017 revenue in Europe
totaled €95.3 million, up 2.2% at constant exchange rates, given
the now effective prioritization of product/market pairings (for
X-rays in particular). Sales are still growing strongly in the
Other Markets, especially in Asia, a priority development zone for
the Group, as well as in the US and Latin America, and particularly
Brazil.
At constant exchange rates,
activity grew in every segment:
-
The MRI segment reported
revenue of €65.6 million, representing a 10.4% increase, thanks to
steady sales of Dotarem® in the
US
-
The X-ray segment rose by
4.2% to €94.5 million, particularly due to the excellent
performance of Optiject®
-
Sales were stable in the IRT segment at €12.1 million (+0.9%)
-
The Imaging Solutions and
Services (ISS) segment gained considerable ground (+27.5%) with
revenue of €20.0 million, confirming the trend that started at the
end of 2016.
Outlook for 2017: return to growth
In less than eighteen months, the
declining sales of the business acquired at the end of 2015 were
strategically turned around. The strong performance in the 1st
quarter of 2017 for all four product segments reflects this success
achieved and gives a confidence boost to the Group, which is
confirming its full-year growth target.
Upcoming
events:
Publication of H1 2017 revenue
July 27, 2017, after trading
Guerbet is a pioneer in the
contrast agent field, with 90 years' experience, and is the only
pharmaceutical group dedicated to medical imaging worldwide. It
offers a comprehensive range of X-Ray, Magnetic Resonance Imaging
(MRI) and Interventional Radiology and Theranostics (IRT) products,
along with a range of injectors and related medical devices to
improve the diagnosis and treatment of patients. To discover new
products and ensure future growth, Guerbet invests heavily in
R&D, spending around 9% of its sales each year. Guerbet (GBT)
is listed on Euronext Paris (Segment B - Mid Caps) and generated
€776 million in revenue in 2016.
For more information about Guerbet,
please visit www.guerbet.com
Jean-François Le Martret
Chief Financial Officer
(+33)(0)1 45 91 50 00
|
Financial Communications
Benjamin Lehari
(+33)(0)1 56 88 11 25
blehari@actifin.fr
Press
Jennifer Jullia
(+33)(0)1 56 88 11 19
jjullia@actifin.fr
|
Press release
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: GUERBET via Globenewswire
Guerbet (EU:GBT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Guerbet (EU:GBT)
Historical Stock Chart
From Jul 2023 to Jul 2024